Keyphrases
MTOR Inhibitor
100%
Adverse Event Management
100%
Adverse Events
80%
Everolimus
40%
Hyperglycemia
20%
Dyslipidemia
20%
Hypertension
20%
Anemia
20%
Immunosuppression
20%
Diabetes
20%
Immunosuppressive Agents
20%
Therapeutic Potential
20%
Sirolimus
20%
Proteinuria
20%
Advanced Renal Cell Carcinoma
20%
Oncology
20%
Solid Organ Transplant Recipients
20%
Temsirolimus
20%
Incisional Hernia
20%
Wound Complications
20%
Gonadal Dysfunction
20%
Cutaneous Adverse Drug Reactions (cADRs)
20%
Inhibitor Therapy
20%
Delayed Graft Function
20%
Mechanistic Aspects
20%
Pneumonitis
20%
Nephrotoxicity
20%
Inhibitor Treatment
20%
Stomatitis
20%
PubMed Search
20%
Antineoplastic Drugs
20%
Lymphocele
20%
Ovarian Toxicity
20%
Ridaforolimus
20%
Medicine and Dentistry
Adverse Event
100%
Mammalian Target of Rapamycin Inhibitor
100%
Everolimus
33%
Malignant Neoplasm
16%
Clear Cell Renal Cell Carcinoma
16%
Anemia
16%
Immunosuppressive Treatment
16%
Transplantation
16%
Diabetes
16%
Hyperglycemia
16%
Immunosuppressive Drug
16%
Dyslipidemia
16%
Oncology
16%
Proteinuria
16%
Side Effect
16%
Temsirolimus
16%
Incisional Hernia
16%
Pneumonia
16%
Gonad Dysfunction
16%
Wound Healing
16%
Rapamycin
16%
Delayed Graft Function
16%
Nephrotoxicity
16%
Lymphocele
16%
Anticarcinogen
16%
Stomatitis
16%
Ridaforolimus
16%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Mammalian Target of Rapamycin Inhibitor
100%
Everolimus
33%
Hyperglycemia
16%
Dyslipidemia
16%
Malignant Neoplasm
16%
Anemia
16%
Renal Cell Carcinoma
16%
Immunosuppressive Agent
16%
Side Effect
16%
Rapamycin
16%
Temsirolimus
16%
Proteinuria
16%
Pneumonia
16%
Gonad Dysfunction
16%
Delayed Graft Function
16%
Nephrotoxicity
16%
Wound Healing
16%
Anticarcinogen
16%
Stomatitis
16%
Incisional Hernia
16%
Lymphocele
16%
Ridaforolimus
16%